Trials / Completed
CompletedNCT02713204
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 365 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN910-3 | |
| DRUG | Intravitreal Aflibercept Injection (IAI) |
Timeline
- Start date
- 2016-03-31
- Primary completion
- 2017-10-03
- Completion
- 2017-10-03
- First posted
- 2016-03-18
- Last updated
- 2019-05-07
- Results posted
- 2019-05-07
Locations
87 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02713204. Inclusion in this directory is not an endorsement.